ADL Amdl,

TUSTIN, Calif., Sept. 25 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that Jade Pharmaceutical Inc., the registration agent in China for AMDL, has submitted an application with the China State Food and Drug Administration (SDFA) for approval to market AMDL's DR-70(R) cancer test. The SDFA has begun the approval process and DR-70(R) is undergoing standard product review by the Beijing Institute of Medical Device Quality Supervision and Inspection Center. According to the Drug Discovery News, the worldwide market for cancer diagnostics (including in vitro diagnostics such as AMDL's DR-70(R)) is expected to increase from approximately $4.1 billion in 2004 to an estimated $7.4 billion in 2009. With more than 3 million cancer patients in China, the disease is one of the major causes of death in urban areas and especially in people 65 and older. Chinese government officials see early detection as a key to cutting the morbidity and mortality rate for cancer as well as stemming the costs for treating this disease in its advanced stages. "With a growing urban and rapidly aging population, and the increasing trend toward health awareness by the Chinese people, there is a significant market for cancer diagnostics in China," said Gary Dreher, AMDL CEO. "As living standards increase, promoted by enormous economic development in China, the market demand for early stage cancer detection is certain to grow. It is estimated this year-over-year growth will be 10 percent going forward." Mr. Dreher stressed that "in collaboration with Jade Pharmaceutical, we have significant advantages entering this marketplace compared to competitors, including use of Jade Pharmaceutical's experienced pharmaceutical sales teams, a solid relationship with China's medium to large hospitals and physical examination centers, and an excellent professional relationship with Chinese associations that play a key decision-making role," Mr. Dreher said. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 14 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO, AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright